DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

BACKGROUND: Because the general population is largely naive to H5N1 influenza, antibodies generated to H5 allow analysis of novel influenza vaccines independent of background immunity from previous infection. We assessed the safety and immunogenicity of DNA encoding H5 as a priming vaccine to improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ledgerwood, Julie E, Wei, Chih-Jen, Hu, Zonghui, Gordon, Ingelise J, Enama, Mary E, Hendel, Cynthia S, McTamney, Patrick M, Pearce, Melissa B, Yassine, Hadi M, Boyington, Jeffrey C, Bailer, Robert, Tumpey, Terrence M, Koup, Richard A, Mascola, John R, Nabel, Gary J, Graham, Barney S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2011
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185472/
https://www.ncbi.nlm.nih.gov/pubmed/21975270
http://dx.doi.org/10.1016/S1473-3099(11)70240-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185472/
https://www.ncbi.nlm.nih.gov/pubmed/21975270
http://dx.doi.org/10.1016/S1473-3099(11)70240-7

Ejemplares similares